SCHEMBL4466624

SCHEMBL4466624

O=C(O)c1cc2cc(OCc3ccc(Cl)cn3)ccc2[nH]1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.61
ALDH1A1 P00352 2/20 0.61
HPGD P15428 2/20 0.61
HSD17B10 Q99714 2/20 0.61
CYP1A2 P05177 1/20 0.61
CYP2C9 P11712 1/20 0.61
SRD5A2 P31213 1/20 0.61
F7 P08709 1/20 0.56
F3 P13726 1/20 0.56
CFD P00746 1/20 0.50
KMT2A Q03164 1/20 0.50
PDGFRB P09619 3/20 0.49
PDGFRA P16234 2/20 0.49
FLT3 P36888 3/20 0.47
SMAD3 P84022 1/20 0.47
PLA2G4A P47712 1/20 0.45
NR1H4 Q96RI1 1/20 0.43
PIN1 Q13526 1/20 0.43
PDPK1 O15530 1/20 0.43
LMNA P02545 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4465748 0.83 KDM4E (0.58) KDM4EALDH1A1HPGDHSD17B10CYP1A2
SCHEMBL4311301 0.81 KDM4E (0.71) KDM4EALDH1A1HPGDHSD17B10CYP1A2
SCHEMBL4464851 0.79 ALDH1A1 (0.68) KDM4EALDH1A1HPGDHSD17B10CYP1A2
SCHEMBL6542663 0.77 KDM4E (0.69) KDM4EALDH1A1HPGDHSD17B10CYP1A2
SCHEMBL4467264 0.77 PYGL (0.50) KDM4EALDH1A1KMT2A
SCHEMBL630515 0.76 SRD5A2 (1.00) KDM4EALDH1A1HPGDHSD17B10CYP1A2
SCHEMBL9816551 0.76 KMT2A (0.78) KDM4EALDH1A1HPGDHSD17B10CYP1A2
SCHEMBL2767179 0.75 KDM4E (0.65) KDM4EALDH1A1HPGDHSD17B10CYP1A2
SCHEMBL4322888 0.74 NR4A2 (0.63) KDM4ESRD5A2TSHRMRGPRX4
SCHEMBL4371734 0.74 PDGFRB (0.71) KDM4EALDH1A1HPGDHSD17B10CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7531668-B2 2-arylcarboxamide-nitrogenous heterocycle compound BANYU PHARMACEUTICAL CO., LTD. (JP) 2009-05-12 US disclosed
US-20070299070-A1 2-Arylcarboxamide-Nitrogenous Heterocycle Compound MSD K.K. (JP) 2007-12-27 US disclosed
EP-1798221-A1 2-ARYLCARBOXAMIDE-NITROGENEOUS HETEROCYCLE COMPOUND BANYU PHARMACEUTICAL CO., LTD. (JP) 2007-06-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070299070-A1 2-Arylcarboxamide-Nitrogenous Heterocycle Compound MCHR2, MCHR1, NPY2R KDM4E 2454/4885ALDH1A1 1060/4885HPGD 1342/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.